Original research

Women and men exhibit distinct gut microbial profiles linked to colorectal cancer development

Bucher-Johannessen, C. [1,2,3]*, Kværner, AS.[4]*, Birkeland, E.[5], Botteri E.[2,4], Avershina, E.[1,5], Bemanian, V.[6], Hoff, G.[4,7], Randel, KR.[4], Hovig, E.[1,3], Berstad, P.[4], Rounge, TB.[1,4,5]

*Shared first authorship

Author Affiliations:

Department of Tumour Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway

Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway

Department of Informatics, University of Oslo, Oslo, Norway

Department of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health; Oslo, Norway

Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway

Department of Pathology, Akershus University Hospital, Lørenskog, Norway

Department of Research, Telemark Hospital, Skien, Norway

Corresponding Authors

Ane Sørlie Kværner

Tel: +47 901 157 47

Mailing address: Cancer Registry of Norway, Norwegian Institute of Public Health,
Postboks 5313 Majorstuen, 0304 Oslo, Norway

E-mail address: a.s.kvarner@gmail.com

ORCID identifier: 0000-0001-6247-7304

Trine B. Rounge

Tel: +47 996 043 04

Mailing address: University of Oslo, Postbox 1068 Blindern, 0316 Oslo, Norway

E-mail address: trinro@uio.no

ORCID identifier: 0000-0003-2677-2722

Sources of Support

This project was made possible by funding from the Norwegian Cancer Society (grant
nos. 190179 and 198048), the Norwegian Cancer Society's umbrella organization for
cancer research ("Kreftforeningens paraplystiftelse for kreftforskning"), the Research
Council of Norway (grant no. 280667), and the South-Eastern Norway Regional Health
Authority (grant nos. 2022067 and 2020056). The BCSN trial study was funded by the
Norwegian Parliament (Norwegian national budget from 2011). The bowel preparation
used for colonoscopy was provided free of charge by Ferring Pharmaceuticals. The
funders had no role in study design, data collection, analysis, interpretation, or the writing
of this article.

Short running head: Sex, the gut microbiome and colorectal cancer

Abbreviations

ACME: Average causal mediation effect

ADE: Average direct effect

AICR: American Institute for Cancer Research

ANOVA: Analysis of variance

ASV: Amplicon sequence variant

BCSN: Bowel Cancer Screening in Norway

BH: Benjamini-Hochberg

BMI: Body mass index

CI: Confidence interval

CRC: Colorectal cancer

FFQ: Food frequency questionnaire

FIT: Fecal immunochemical test

GO: Gene ontology

KBS: Kostberegningssystem

MaAsLin: Microbiome multivariable associations with linear models

NCT: National clinical trial

OR: Odds ratio

PCoA: Principal coordinate analysis

PERMANOVA: Permutational multivariate analysis of variance

PPV: Positive predictive value

SD: Standard deviation

TE: Total effect

TSS: Total sum scaling

WCRF: World Cancer Research Fund

Trial Registration: The BCSN is registered at clinicaltrials.gov (National clinical trial
(NCT) no. 01538550).

Abstract

Background: The gut microbiome has emerged as a promising source of biomarkers to enhance early detection of colorectal cancer (CRC). However, sex-specific differences in gut microbial profiles and their relationship to CRC risk remain underexplored.

Objective: To investigate sex differences in screening-detected colorectal lesions and gut microbial profiles, as well as the potential for sex-specific associations between the gut microbiome and colorectal lesions.

Methods: This cross-sectional study included 1,034 faecal immunochemical test-positive screening participants aged 55–77 years recruited from the Norwegian CRCbiome study. Shotgun metagenomic sequencing was used to generate taxonomic and functional profiles of the gut microbiome, which were integrated with clinicopathological, demographic, and lifestyle data. Associations between sex, colorectal lesions, and microbial characteristics – including α-diversity, β-diversity, and abundances of bacterial species and functions – were assessed, including their interactions.

Results: Male participants had significantly higher odds of presenting with both non-advanced (OR: 1.50; 95% CI: 1.00–2.26) and advanced (OR: 1.46; 95% CI: 1.10–1.93) colorectal lesions compared to women. Gut microbial profiles differed markedly by sex, demonstrating compositional shifts and distinct bacterial profiles (19 taxa and 58 functions more abundant in men, 13 bacteria and 41 functions more abundant in women). In women, microbial α-and β-diversity varied across lesion subtypes, whereas no such differences were observed in men. Interaction analyses identified 5 bacteria and 6 functions that were differentially associated with colorectal lesions by sex.

99   **Conclusion:** This study highlights sex-specific differences in the gut microbiome and their

100   association with colorectal lesions, emphasising the need to take sex into account in future

101   research aiming to enhance CRC prevention strategies and treatment.

102   **Keywords**: Sex, gut microbiome, effect modification, mediation, colorectal lesions, colorectal

103   cancer, colorectal cancer screening

Introduction

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide (1). Both CRC incidence and mortality show a male predominance, a pattern which remains consistent across countries, despite significant variations in incidence rates (2, 3). Variations in exposure to, and effects of, dietary and lifestyle factors are likely contributors to the observed disparities (4); however, the extent of their contribution remains unclear. Projections suggest that the observed sex disparities in CRC risk are likely to persist in the coming decades (2).

CRC screening has the potential to reduce both CRC incidence (5-8) and mortality (5-12). Faecal immunochemical testing (FIT) is the most widely used screening method (13), and is recommended as the preferred test by EU guidelines (14). FIT detects haemoglobin in stool, with positivity thresholds varying from >10 to >150 μg/g across European screening programs (15), prompting follow-up diagnostic colonoscopy. While FIT has a good sensitivity for colorectal cancers (16), it is less accurate for precancerous lesions (16) and lesions located in the proximal colon (17). Additionally, FIT-based screening has been criticised for potentially disadvantaging women (18). This may be due to anatomical, physiological, and/or pathogenetic differences affecting diagnostic performance of either the FIT (19-23) or the colonoscopy (24-27). Complementary strategies to improve screening efficacy and equity are needed.

Emerging evidence supports a role of the gut microbiome in CRC development (28-33). Proposed mechanisms include interaction with the immune system (34-36), induction of inflammation and oxidative stress (37-39), cross-talk with the endocrine system (40-42), and production of bioactive compounds, including metabolites, toxins, and virulence factors (43-49). A growing number of studies suggest that specific microbes — alone or in combination with other biomarkers — can be used to predict colorectal lesions (50, 51). As sex impacts the microbial profile (52-55), it is plausible that the microbiome's role in CRC development, as well as its potential as a biomarker

source, varies by sex. While there is some evidence supporting this hypothesis (56-63), existing

studies are either limited by reliance on mouse models (57, 60, 64, 65) or insufficient sample sizes

(58, 61, 63) and/or lack of control for dietary and lifestyle exposures (56, 58, 59, 61-63) – important

predictors of both CRC risk (66, 67) and microbial variation (68, 69).

To enhance our understanding of the potential interactions between sex and the gut microbiome

in CRC development, we analysed data from a large CRC screening study in Norway, combining

metagenomic taxonomic and functional profiles with comprehensive clinicopathological, lifestyle,

and demographic information. Specifically, our objectives were to i) identify differences between

men and women in a) the prevalence of screen-detected colorectal lesions and b) gut microbial

profiles, controlling for lifestyle and demographic factors, and ii) explore potential pathways

through which these factors may interact.

Methods and materials

Study population

In this study, we used data from the CRCbiome study, which has been described in detail

previously (70). The CRCbiome study was initiated in 2017 and invited participants from the large

Bowel Cancer Screening in Norway pilot trial (BCSN) (n=139,291) (71). The BCSN started in

2012, where Norwegian citizens from selected municipalities surrounding the capital of Oslo

(aged 50-74 years) were invited to either undergo once-only sigmoidoscopy or FIT test biennially.

The CRCbiome study recruited participants from the FIT arm (rounds 2-4), using a positive FIT

test as an inclusion criterion (≥15 µg haemoglobin/g faeces). Participants with a positive FIT test

were referred to colonoscopy, where potential neoplastic lesions were removed. Participants were

asked to fill in a lifestyle and demographic questionnaire (LDQ) and a food frequency

questionnaire (FFQ) prior to the scheduled colonoscopy. Return of either questionnaire provided

consent and enrolment into the study. Samples were excluded from analyses if they had

insufficient sequencing depth, defined as less than 1 gigabase of sequencing output after quality

control. Additionally, samples were excluded if the individuals did not attend follow-up

colonoscopy or presented with one or two non-advanced neoplastic lesions or serrated lesions

during screening.

The BCSN trial and the CRCbiome study have been approved by the Regional Committee for

Medical and Health-related Research Ethics in Southeast Norway (REK ref: 2011/1272 and

63148, respectively. The BCSN trial is registered at clinicaltrials.gov (Clinical Trial (NCT) no.:

01538550).

Outcome measures

In this study, participants were classified into three colonoscopy groups: 1) "No neoplasia",

including individuals without lesions, those with ≥1 non-neoplastic lesion (e.g., inflammatory or

granulation tissue polyps), and those with other findings (e.g., diverticulitis, haemorrhoids, or IBD);

2) "Non-advanced neoplastic lesions, and 3) "Advanced lesions", which included those with ≥1

advanced serrated lesion, ≥1 advanced adenoma, or CRC. Advanced adenoma was defined as

any adenoma with at least one of the following characteristics: villous histology (≥25% villous

components), high-grade dysplasia, or a polyp size ≥10 mm. Advanced serrated lesions were

defined as serrated lesions with a size ≥10 mm or evidence of dysplasia. CRC was classified as

the presence of adenocarcinoma originating in the colon or rectum.

Questionnaire data

Lifestyle and demographic information was collected using a self-administered four-page

questionnaire, described in detail elsewhere (70). The questions relevant to the current study

captured data on demographic factors (national affiliation, education, employment status, and

marital status), clinical factors (family history of CRC and diagnosis of chronic bowel disorders),

and lifestyle factors (smoking and snus habits, and physical activity level).

Dietary intake data were obtained using a validated 14-page semi-quantitative FFQ, developed

and validated at the Department of Nutrition, University of Oslo (72-77). This FFQ assessed

habitual dietary intake over the preceding year and provided estimates of total energy intake,

macronutrient and micronutrient intake, as well as intake of foods and beverages (256 in total).

Dietary intake in grams per day was calculated using the dietary calculation system KBS (short

for "**K**ost**b**eregnings**s**ystem"). The most recent database at the time (AE-18) was used, which is

an extended version of the 2018 Norwegian Food Composition Table (78).

The FFQ also recorded self-reported body weight (kg) and height (cm), which were used to

calculate body mass index (BMI).

Based on data from the two questionnaires, a seven-point diet and lifestyle score was created to

measure adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for

Cancer Research (AICR) cancer prevention recommendations. The recommendations were

operationalised using a standardised scoring system developed by Shams-White *et al*. (79, 80),

as described in detail elsewhere (81).

Sample collection and DNA extraction

The FIT tests were collected at home by the participants and sent by mail to the testing facility.

For DNA extraction, leftover FIT samples were buffered, and 500 µL aliquots were used for

analysis. DNA extraction utilised the QIAsymphony DSP Virus/Pathogen Midikit (Qiagen, Hilden,

Germany), according to the instruction manual, with additional off-board lysis and bead-beating.

Extracted DNA was buffered in 60 µl AVE buffer. DNA from FIT tubes show no detectable cross-

contamination and harbours diverse microbial communities (82, 83).

Library preparation and sequencing

Following extraction, sample quality was measured on a NanoDrop 2000 spectrophotometer

(Thermo Fisher Scientific, MA, USA) and DNA concentration using a Qubit Fluorometer (Thermo

Fisher Scientific, MA, USA). Samples with a DNA concentration above 0.7 ng/µl were considered

eligible for library preparation and sequencing. Library preparation was performed using the

Nextera DNA Flex Library Prep Reference Guide according to the manual with the modification

of reducing reaction volume to one-fourth of the reference. Sample pools were sequenced on the

Illumina NovaSeq system (Illumina Inc., CA, USA), resulting in paired-end 151 bp reads. Library

preparation and sequencing were performed at the FIMM Technology Centre in Helsinki, Finland.

Bioinformatics

Sequencing reads were quality controlled using KneadData (v0.12)

(http://huttenhower.sph.harvard.edu/kneaddata) with default settings to remove adapters, low-

quality bases and reads mapping to the human genome. MetaPhlAn4 (84) (v4.0.6) was used to

identify the relative abundance of microbial taxa and bacterial taxa for use in subsequent

analyses. Further, HumanN3 was used (85) (v3.7) to determine gene content using the

mpa_vOct22_ChocoPhlAn_202212 pangenome database and the UniRef90 (86) database for

classifying the gene families into Gene Ontology (GO) annotations (87, 88) covering biological

processes, molecular functions and cellular components – hereafter collectively referred to as

functions. Abundance of gene content from HumanN3 was scaled by the number of quality-

assessed reads per million.

Statistics

We summarised continuous variables using the median value with interquartile range and

categorical variables using counts with percentages. Within-group differences were examined

using Kruskal-Wallis or Wilcoxon rank sum test for continuous variables and Pearson`s Chi-

squared or Fisher`s exact test for categorical variables, as appropriate.

To ensure complete datasets, multivariate imputation by chained equations was performed using

the R package *mice* (89). The imputed variables included marital status, employment status,

smoking status and the WCRF/AICR score. All variables listed in Table 1 were used as predictors

in the imputation process. All analyses reported in the manuscript are based on the imputed

dataset.

We ran a multinomial logistic regression analysis to study the association between sex and

colonoscopy findings (i.e., a) no neoplasia (reference category); b) non-advanced neoplastic

lesions; and c) advanced lesions). The analysis was adjusted for the following covariates: Model

1) age (continuous) and screening centre (centre 1, centre 2); model 2: model 1 covariates,

employment status (employed, retired, other), marital status (not married/non-cohabiting,

married/cohabiting), smoking status (never smoked, ever smoked) and the WCRF/AICR score

(continuous). Covariates were selected based on the association patterns observed in **Table 1**

and **Supplementary Table 1**. Unless otherwise specified, the subsequent analyses were

conducted using these covariate sets.

To investigate microbial differences between sexes, α-diversity, β-diversity, and differential

abundance of bacterial species and functions were assessed. Differences in α-diversity indices

(Shannon and Inverse Simpson) were analysed using analysis of variance (ANOVA). β-diversity

differences were assessed using the Bray-Curtis dissimilarity index, calculated with the vegdist

function in the R package *vegan* (90) and tested for significance using permutational analysis of

variance (PERMANOVA) with 999 permutations. Differentially abundant taxa and functions were

identified using *MaAsLin2* (91) with the following settings: a minimum abundance threshold of

10%; log2 transformation with zero values replaced by a pseudo-count equal to half the lowest

observed value across all features; normalisation set to none for bacterial abundances and total

sum scaling for functions; and a linear model. Prior to analysis, functions strongly correlated with

bacterial species (Spearman's correlation coefficient > 0.5) were excluded to mitigate the risk of

spurious associations driven by bacterial variation. P-values were adjusted for multiple testing

using the Benjamini-Hochberg (BH) correction method.

To investigate whether the gut microbiome mediated the association between sex and colorectal

lesions, a causal mediation analysis was performed following the approach described by Kværner

et al. (92). A sex-associated microbial score was developed to represent the influence of sex on

the gut microbiome. Two versions of the microbial score were developed based on differential

abundance analyses: one minimally adjusted score, allowing differences in lifestyle and

demography between sexes to contribute to microbial variation, and another fully adjusted score.

The scores were calculated as the log-transformed ratios of the summed abundances of microbial

species positively associated with sex to the summed abundances of species negatively

associated with sex. To reduce bias, a five-fold cross-validation approach was used for generation

of the scores, where for each subset, the microbial scores were derived using the microbial

species identified as significantly associated with sex in the remaining subsets. In the mediation

analysis, sex was treated as the independent variable, colorectal lesions as the outcome, and the

sex-associated microbial score as the mediator. To enhance statistical power, non-advanced

neoplastic lesions were grouped with advanced lesions. The analysis was adjusted for the same

set of covariates as in model 2, along with the cross-validation partition identity to account for

variability introduced by the score development process. Mediation effects were estimated using

the R package *mediation* (93) and the function mediate. This involved fitting two models: 1) a

multivariate linear regression model to assess the association between sex and the sex-

associated microbial score, and 2) a generalised linear model to evaluate the association between

the sex-associated microbial score and colorectal lesions, controlling for sex. We report point

estimates and non-parametric bootstrap confidence intervals using 1,000 bootstrap simulations.

To validate these findings, an alternative mediation analysis was performed using the R package

medflex (94) and the function neModel. This approach relies on a natural effects model with

imputation of nested counterfactuals, ensuring that the mediation effects are robust and not

dependent on specific covariate levels.

To investigate sex-specific influences of the gut microbiome on colorectal lesions, sex-stratified

analyses were conducted for α-diversity, β-diversity, and differential abundance of microbial taxa

and functions. Interactions were examined using the entire dataset. For α- and β-diversity, sex-

specific associations were examined by including interaction terms for sex and lesion status.

Bacterial species and functions that were differently abundant in advanced lesions at a BH-

corrected p-value of 0.2 and 0.15, respectively, in either men or women, were further analysed

for interaction effects in the entire dataset using multinomial logistic regression, including

interaction terms of sex and the log-transformed abundance values.

To address potential disparities in the distribution of lesion subtypes between men and women,

stratified analyses were conducted comparing individuals with advanced serrated lesions to those

without any neoplasia. Analyses were also performed without the inclusion of the less common

advanced serrated lesions.

All analyses were performed using the R statistical environment with the main packages *tidyverse*

(95) (v1.3.1), *rstatix* (96) (v0.7.0), *nnet* (97) (v7.3-16), *mice* (89) (v3.14.0), *vegan* (90) (v2.5.7),

MaAsLin2 (91) (v1.12.0), *mediation* (93) (v4.5.0) and *medflex* (94) (v0.6-7).

The significance level was set to p <0.05 for all analyses.

Results

Characteristics of the study population overall and by sex

Participants' characteristics overall and stratified by sex are presented in Table 1. The study included more men (n=582; 56%) than women (n=452; 44%). Men were more likely to be married, possess a university degree, and be employed, whereas women more frequently reported bowel disorders. In terms of lifestyle factors, men were more likely to use tobacco snus, have a higher BMI, and lower adherence to cancer prevention recommendations compared to women. No difference in lesion location (proximal versus distal) was observed between men and women. However, there was a significant difference in lesion subtypes, women more often presenting with advanced serrated lesions than men. In both sexes, the presence of screen-detected lesions (whether non-advanced or advanced) was associated with older age, being retired, being unmarried or not cohabiting, being screened at Bærum Hospital and having a higher alcohol consumption (Supplementary Table 1).

Table 1. Participants characteristics overall (n=1,034) and among women (n=452) and men (n=582)[1].

Variables	n	Female[1] (n = 452)	Male[1] (n = 582)	Overall[1] (n = 1,034)	p-value[2]
Age, years	1,034	67 (62, 72)	67 (62, 72)	67 (62, 72)	0.901
Screening center, n (%)	1,034				0.830
Moss		250 (55)	318 (55)	568 (55)	
Bærum		202 (45)	264 (45)	466 (45)	
National affiliation, n (%)	989				0.285
Norwegian		415 (94)	504 (92)	919 (93)	
Non-norwegian		27 (6.1)	43 (7.9)	70 (7.1)	
Family history of CRC, n (%)	923	87 (21)	98 (19)	185 (20)	0.506
Localisation	584				0.821
Distal only		61 (26)	89 (25)	150 (26)	
Any proximal		170 (74)	264 (75)	434 (74)	
Advanced serrated lesions	584				**0.031**
Yes		60 (26)	64 (18)	124 (21)	
No		171 (74)	289 (82)	460 (79)	
Marital status, n (%)	1,013				**<0.001**
Not married/non-cohabiting		121 (27)	81 (14)	202 (20)	

	n				P-value
Married/cohabiting		326 (73)	485 (86)	811 (80)	
Education, n (%)	1,008				**0.021**
Primary school		102 (23)	94 (17)	196 (19)	
High school		174 (39)	219 (39)	393 (39)	
University/college		168 (38)	251 (45)	419 (42)	
Employment status, n (%)	1,015				**0.002**
Employed		119 (27)	203 (36)	322 (32)	
Retired		259 (58)	307 (54)	566 (56)	
Other		69 (15)	58 (10)	127 (13)	
Bowel disorder, n (%)	1,002				**0.001**
No bowel disease		357 (82)	501 (89)	858 (86)	
Any disorder		81 (18)	63 (11)	144 (14)	
Smoking status, n (%)	1,013				0.384
Never smoked		173 (39)	204 (36)	377 (37)	
Ever smoked		274 (61)	362 (64)	636 (63)	
Snus status, n (%)	971				**<0.001**
Non snuser		412 (99)	489 (88)	901 (93)	
Snuser[3]		6 (1.4)	64 (12)	70 (7.2)	
Energy intake, kcal/day	1,007	1,914 (1,572, 2,374)	2,399 (1,912, 2,900)	2,181 (1,733, 2,717)	**<0.001**
Alcohol intake, g/day	1,007	5 (1, 12)	12 (4, 24)	9 (2, 19)	**<0.001**
BMI, kg/m^2	1,000	25.9 (23.1, 28.8)	27.1 (24.6, 29.3)	26.5 (24.1, 29.3)	**<0.001**
Physical activity, min/week	1,015	135 (0, 300)	105 (0, 360)	105 (0, 300)	0.354
Recent antibiotic use, n (%)	964	69 (16)	67 (12)	136 (14)	0.097
WCRF/AICR score, points	943	2.5 (2.0, 3.0)	2.3 (1.8, 2.8)	2.5 (2.0, 3.0)	**<0.001**

[1]*Values are median (IQR) for continuous variables and n (%) for categorical variables.*
[2]*P-values are derived from Wilcoxon rank sum and Pearson`s Chi-squared testing.*
[3]*To be defined as a snuser one had to be a regular or occasional user or having quit consumption within the last ten years.*
Abbreviations: AICR; American Institute of Cancer Research, BMI; Body mass index, CRC; colorectal cancer, g; gram, n; number, WCRF; World Cancer Research Fund

Sex and colorectal lesions

Table 2 shows the associations between sex and colonoscopy findings. Compared to women, men were more likely to present with non-advanced neoplastic lesions and advanced lesions, with odds ratios (ORs) of 1.55 (95% confidence intervals (CI) 1.05, 2.29) and 1.47 (95% CI 1.12, 1.92), respectively. Additional adjustment for lifestyle and demographic factors only modestly attenuated the effect estimates (ORs of 1.50 (95% CI 1.00, 2.26) and 1.46 (95% CI 1.10, 1.93), respectively).

Table 2. Odds ratios (ORs) and 95% confidence intervals (CIs) for presence of non-advanced neoplastic lesions[1] and advanced lesions[2] relative to controls by sex (n=1,034)[3].

	No neoplasia (n=450)	Non-advanced neoplastic lesions (n=142)			Advanced lesions (n=442)		
	<u>n</u>	<u>n</u>	<u>OR (95% CI)</u>	<u>p-value</u>	<u>n</u>	<u>OR (95% CI)</u>	<u>p-value</u>
Female	221	55	Ref.		176	Ref.	
Male							
Model 1	229	87	1.55 (1.05, 2.29)	**0.028**	266	1.47 (1.12, 1.92)	**0.005**
Model 2	229	87	1.50 (1.00, 2.26)	0.052	266	1.46 (1.10, 1.93)	**0.009**

[1]Includes any adenoma (adenomatous polyp) not fulfilling the criteria of being advanced.
[2]Includes advanced adenoma, defined as any adenoma with either villous histology (≥25% villous components), high-
grade dysplasia or polyp size greater than or equal to 10 mm; advanced serrated lesions, defined as any serrated
lesions with size ≥ 10 mm or dysplasia; and colorectal cancer, defined as presence of adenocarcinoma arising from the
colon or rectum.

[3]Odds ratios (ORs) and 95% confidence intervals (CIs) are obtained from multinomial logistic regression analyses

adjusting for the following covariates: Model 1: age (continuous) and screening centre (Moss, Bærum); model 2: model

1 covariates, employment status (employed, retired, other), marital status (not married/non-cohabiting,

married/cohabiting), smoking status (never smoked, ever smoked) and the WCRF/AICR score (continuous).

Sex and gut microbial features

Among the 1,034 included participants, the mean (SD) number of paired-end reads was

13,030,984 (3,883,470). A total of 2,756 bacterial species were identified, with a mean (SD) of

239 (68) species per sample. The mean (SD) of species per sample was 241 (66) and 237 (69)

in men and women, respectively.

<u>α- and β-diversity</u>

Associations of sex with α- and β-diversity are illustrated in Figure 1A-B. There were no

associations between sex and the two α-diversity indices (neither Shannon nor the Inverse

Simpson index, Figure 1A). However, notable differences in β-diversity were observed between

the sexes both in the control group (R^2=0.004, p=0.002, Supplementary Figure 1) and the

population as a whole (R^2=0.003, p=0.001, Figure 1B), which were attenuated, but remained

statistically significant after adjusting for lifestyle and demographic factors (R^2=0.002, p=0.001).

Figure 1: Differences in α-diversity (A), β-diversity (B) and bacterial species abundance (C) between

women and men. A) Within-sample diversity for the two indices Inverse Simpson (left) and Shannon (right)

in women and men. B) Principal coordinates analysis (PcoA) plot of the Bray-Curtis dissimilarity index

between women and men. C) Differentially abundant bacterial species comparing women and men. Effect

estimates are presented as log2FoldChange (Log2FC) with 95% confidence intervals (CI). Species were

selected for visualisation based on BH-adjusted p-values <0.05. Features shown in red were significantly

more abundant in men, while those in blue were significantly less abundant. All analyses were adjusted for

age (continuous), screening centre (Moss, Bærum), employment status (employed, retired, other), marital

status (not married/non-cohabiting, married/cohabiting), smoking status (never smoked, ever smoked), and

the WCRF/AICR score (continuous).

Differentially abundant bacteria and functions

In total, 52 bacterial species were differentially abundant between women and men. Of these, 32

(62%) species remained statistically significant after adjusting for lifestyle and demographic

factors (Figure 1C, Supplementary Data 1). Nineteen were more abundant in men and 13 in

women. The strongest associations with male sex were observed for *Paraprevotella clara*,

Bifidobacterium adolescentis, *Phocaeicola vulgatus*, and *Alistipes putredinis*. In contrast, the

species most strongly associated with female sex were *Eggerthella lenta* and *Streptococcus*

thermophilus. At the functional level, 174 showed differential abundance between the sexes. Of

these, 99 (57%) remained statistically significant after adjusting for lifestyle and demographic

factors (Supplementary Figure 2, Supplementary Data 2), with 58 functions more abundant in

men and 41 in women. In men, the most enriched molecular functions included hyaluronic acid

binding, cytidylyltransferase activity, serine-type carboxypeptidase activity, inositol-3-phosphate

synthase activity, pyroglutamyl-peptidase activity, and cysteine-type endopeptidase activity.

Enriched biological processes in men included the negative regulation of fatty acid biosynthetic

processes, uroporphyrinogen III biosynthetic processes, and inositol biosynthetic processes. In

women, the most enriched molecular functions were guanidinobutyrase activity, N-

methylhydantoinase (ATP-hydrolyzing) activity, and protein-macromolecule adaptor activity.

Enriched biological processes in women included protein glycosylation and nickel cation

transport, while the Smc5-Smc6 complex was the most enriched cellular component.

Figure 2. Differences in α-diversity (A), β-diversity (B-C) and abundance of bacterial species (D) between

colonoscopy groups among women and men. A) Within sample diversity for the two indices Inverse

Simpson (left) and Shannon (right) for the colonoscopy groups, no neoplasia (nn), non-advanced neoplastic

lesions (nanl) and advanced colorectal lesions (al) in women and men. B-C) Principal coordinates analysis

(PCoA) plot of the Bray Curtis dissimilarity index between colonoscopy groups in women (B) and men (C).

D) Differentially abundant bacterial species across colonoscopy groups among women and men. Effect

estimates comparing individuals with advanced colorectal lesions to those with no neoplasia are presented

as log2FoldChange (log2FC) with 95% confidence intervals (CI). Bacterial species were selected for

visualisation based on a BH-adjusted p-value of <0.2 in either sex. Triangle indicates significant interaction

term (sex and bacterial abundance) tested in a multinomial logistic regression model (p<0.05). All analyses

were adjusted for age (continuous), screening centre (Moss, Bærum), employment status (employed,

retired, other), marital status (not married/non-cohabiting, married/cohabiting), smoking status (never

smoked, ever smoked), and the WCRF/AICR score (continuous). Abbreviations: *Oscillospiraceae*

bacterium Marse…; *Oscillospiraceae* bacterium Marseille-Q3528, sign; significant, ns; non-significant.

Potential interactions between sex, the gut microbiome, and colorectal lesions

Interactions between sex, the gut microbiome, and colorectal lesions were explored to answer

two questions: 1) whether the gut microbiome *mediated* the relationship between sex and

colorectal lesions, and 2) whether the association between the gut microbiome and colorectal

lesions differed by sex (*effect modification*).

<u>The gut microbiome as a potential mediator</u>

Based on output from differential abundance analyses, two distinct sex-associated microbial

scores were developed: One based on a minimally adjusted model (n=37 bacterial species) and

another based on a fully adjusted model (n=27 bacterial species). These scores were

subsequently used in causal mediation analyses to examine the potential mediating role of sex-

related bacteria in colorectal carcinogenesis (see Supplementary Tables 2-3 for species

significantly associated with sex in each model). Although neither model yielded statistically

significant results, the fully adjusted model showed a modest trend toward a mediation effect

(Supplementary Table 4). The total effect of sex on colorectal lesions was 0.09 (95% CI: 0.03–

0.14), with an average direct effect (ADE) of 0.08 (95% CI: 0.02–0.13) and an average causal

mediation effect (ACME) of 0.01 (95% CI: -0.00–0.02). Overall, the proportion mediated was 10%

(95% CI: -2%–39%), which was further supported by a nested counterfactual approach, also

estimating a mediated proportion of 10% (Supplementary Table 4).

<u>Sex as an effect modifier</u>

To evaluate whether the association between the gut microbiome and colorectal lesions differed

by sex, sex-stratified analyses were performed for the following microbial measures: 1) α-

diversity, 2) β-diversity, and 3) taxonomic and functional profiles. For all measures, notable sex

differences were observed. Among women, significant differences in both α- and β-diversity were

identified between colonoscopy groups (Figure 2A-B). Women with non-advanced neoplastic

lesions had lower α-diversity compared to those without findings, while women with advanced

lesions had higher α-diversity levels (p<0.05 for all comparisons, Figure 2A). Additionally, distinct

separation among colonoscopy groups was observed in the PCoA plot (R²=0.006, p=0.007,

Figure 2B). Conversely, no significant differences in α- or β-diversity were observed across

colonoscopy groups in men (Figure 2A and C). Interaction tests performed using the entire

dataset yielded p-values of 0.066, 0.171, and 0.530 for the Shannon, Inverse Simpson, and Bray-

Curtis indices, respectively. Analyses comparing advanced serrated lesions with controls yielded

consistent results with our overall findings (Supplementary Figure 3). Significant results remained

when excluding serrated lesions from the advanced lesion group.

For bacterial and function abundance, a sex-specific pattern emerged when comparing the most

extreme colonoscopy groups (no neoplasia vs. advanced lesions). In women, 13 bacteria and 17

functions were differentially abundant between groups, whereas four bacteria and 12 functions

were differentially abundant in men (Figure 2D, Supplementary Figure 4). Among the identified

species, five (*GGB52130 SGB14966*, *Enterocloster bolteae, Faecalibacterium prausnitzii,*

GGB51647 SGB4348, and *Flavonifractor plautii*) were confirmed to be sex-specific in multinomial

logistic regression analyses (p-values for interaction terms <0.05). Notably, *E. lenta* and

Hungatella hathewayi were inversely associated with advanced lesions regardless of sex. Among

the differentially abundant functions, six were confirmed to be sex-specific in multinomial logistic

regression analyses (p-values for interaction terms <0.05). The six functions included one related

to biological processes (regulation of GTPase activity), and five related to molecular functions

(1,4-alpha-glucan branching enzyme activity, dipeptidyl-peptidase activity, 1,4-alpha-glucan

branching enzyme activity (using a glycosylated glycogenin as primer for glycogen synthesis),

hydrolase activity, acting on acid anhydrides, and hydrolase activity, acting on ester bonds).

Discussion

Numerous large studies have examined the gut microbiome as a potential biomarker for CRC, but often overlook the importance of sex (48, 98-100). Our study, including metagenomes from >1000 CRC screening participants, suggests that sex may serve as an effect modifier in the relationship between the gut microbiome and CRC development. Specifically, microbial α- and β- diversity varied across lesion subtypes in women, while no such differences were observed in men. Interaction analyses further identified sex-specific bacterial and functional profiles linked to presence of colorectal lesions. This highlights the importance of considering sex in microbial biomarker studies, potentially extending to other conditions beyond CRC.

Our CRCbiome study included FIT-positive participants recruited from the large Norwegian screening trial BCSN. Consistent with previous studies (21), including results from BCSN (15, 71), we found that men had a significantly higher odds of presenting with both non-advanced neoplastic lesions (55%) and advanced lesions (47%) at follow-up colonoscopy. The higher occurrence of lesions in men could be partially attributed to FIT being less efficient in women. To optimise performance across sexes, sex-specific FIT thresholds have been suggested (23). However, adjusting FIT thresholds is not straightforward (20, 23, 101), highlighting the need for complementary strategies

The presence of advanced lesions is strongly linked to modifiable risk factors (67, 102-108), as also documented in our cohorts (81, 92, 109-111). This has led to the hypothesis that the association between male sex and CRC risk, at least in part, is caused by these factors (40, 65, 112). In a large German screening cohort (n=16,000 (113)), known risk factors were found to explain about half (47%) of the excess risk of advanced neoplasia among men, yet a substantial portion remained unexplained. Similarly, in our study, most of the male excess risk remained unexplained (>90%). These observations suggest that modifiable risk factors alone are insufficient to explain the sex gap in CRC risk.

As for differences in the microbial profile between women and men, our study suggests that these

disparities are not merely attributable to differences in exposure profiles. After adjusting for major

contributors to microbial variation, a large part of the sex-microbiome associations remained,

suggesting that intrinsic factors are influential. In support of this, the gut microbiome of women

and men has been found to diverge during puberty – a period marked by significant hormonal

changes (114). In a meta-analysis by Zhang *et al.* (115), including Asian and European cohorts

across a wide age range, sex-specific differences in β-diversity were observed. Interestingly, while

no sex-related differences were observed in the microbiomes of prepubescent children, notable

differences emerged in younger adults before attenuating in individuals over the age of 50.

Our results of distinct sex-specific microbial profiles are in line with previous literature (56, 115-

118), including investigations within CRCbiome, suggesting the presence of sex-specific microbial

profiles linked to alcohol consumption (92). In the present study, we identified thirty-two bacterial

species that were differentially abundant between men and women. We have previously reported

that men in CRCbiome have a higher abundance of *P. succinatutens* (119) and have identified

CRC associations for bacteria of the *Phascolarctobacterium* genus across populations (119-121).

We also found that *B. adolescentis* levels were higher in men. Interestingly, this species has

previously been found to be elevated in older male CRC patients (122) and has been proposed

as a probiotic due to its pro-androgenic activity (123). In line with previous reports, we observed

a higher abundance of *E. lenta* and *G. pamelae* in women (115, 116). Both species potentially

play a role in host physiology and hormonal homeostasis via corticoid conversion to progestin

(124). *E. lenta* has also been reported as being increased in women with premature ovarian

insufficiency (125). The hormone-related *E. lenta* was the only species identified as both sex-

specific and linked to the presence of lesions. A potential influence of sex hormones such as

oestrogen and testosterone on the gut microbiome, which may, in turn, interact with CRC risk,

was recently explored (40). For instance, oestrogens are known to exhibit anti-inflammatory

properties, potentially modulating the gut environment, and influencing cancer risk differently in

men and women, whereas androgens seem to exacerbate cancer development. Indeed, the role

of sex hormones in CRC development has been demonstrated in mice (59, 126).

We found that the associations between the gut microbiome and colorectal lesions differed

between men and women. Specifically, women showed significant differences in both α- and β-

diversity across colonoscopy groups, whereas no such differences were observed in men. Some

studies have investigated sex-based differences in the microbiome within a CRC context (56, 58,

61, 62). These studies typically have a small sample size (N < 90) (58, 61) or include only genus-

level taxonomic resolution (56, 58). Nonetheless, they demonstrate that men and women display

distinct microbial profiles not only among healthy controls but also among individuals with non-

advanced neoplastic lesions and CRC. Interestingly, Liao *et al.* (58) also observed sex differences

and larger variations in women during CRC development compared to men.

We further found that the bacteria *F. plautii*, and *E. bolteae* were associated with advanced lesions

in a sex-specific manner, being lower in female controls. Several studies have found an increase

in *F. plautii* in CRC (127, 128), especially young-onset CRC (129). This species has also been

found to be more prevalent in tubular adenomas than in sessile serrated adenomas (130). *E.*

bolteae (formerly *Clostridium bolteae*), an opportunistic pathogen in the human gut (131),

comprise strains with potentially varying effects on the immune system. When administered

intrarectally, for example, *E. boltae* strains were capable of both alleviating and exacerbating

diarrhoea symptoms in mice colitis models (132). Finally, *F. prausnitzii* was increased in advanced

lesions compared to controls in women. Although this species is believed to exert anti-

inflammatory effects in the gastrointestinal tract (133), research has identified this species as a

complex group consisting of 84 strains, each with diverse functional traits, suggesting a

multifaceted role in human health (134).

Our results, showing that microbial associations with colorectal lesions in general are more

pronounced in women, suggest that microbial biomarkers might be more effective in women than

men. This raises the possibility that incorporating a microbial marker alongside FIT could improve

diagnostic accuracy for women, potentially overcoming the current sex-related limitations of the

test.

A major strength of our study is the extensive microbiome dataset, combined with clinically verified

outcome data, enabling a thorough assessment of screening-relevant outcomes with minimal risk

of misclassification. Additionally, access to detailed lifestyle and demographic data enabled robust

covariate adjustments, distinguishing our study from most prior investigations on this topic (56,

58, 63). However, several limitations must be acknowledged. First, the cross-sectional design

prevents causal interpretations. Second, participation required enrolment in two consecutive

studies: first, the BCSN, followed by CRCbiome, potentially introducing selection bias. In the

BCSN, certain discrepancies existed in participant characteristics between men and women. For

men, non-participation was linked to younger age and not living with a partner, whereas for

women, it was associated with living farther from the screening centre (135, 136). Third, while our

comprehensive covariate adjustments strengthen the study, the possibility of residual

confounding cannot be ruled out.

To conclude, in this FIT-positive CRC screening population, we observe sex-specific microbial

patterns and differences in screening findings. Further, our analyses suggest that sex modifies

the association between the microbiome and CRC. Notably, we observed significant microbial

differences across lesion subtypes in women, but not in men. Additionally, clear sex-specific

distinctions were observed in the bacterial and functional profiles linked to colorectal lesions. Our

results underscore the importance of considering sex in research investigating the gut

microbiome-colorectal lesion axis, with implications for biomarker discovery and tailoring

personalised CRC prevention, detection, and therapy.

Acknowledgements

We would like to acknowledge Jan Inge Nordby for his contribution to sample preparation and lab work. Library preparation and sequencing were performed at the FIMM Technology Centre supported by HiLIFE and Biocenter Finland. We would especially like to thank Harri A. Kangas, and Pekka J. Ellonen. Finally, we want to thank our project coordinator Maja Sigerseth Jacobsen.

Data availability

Data from the CRCbiome project have been deposited in the database Federated EGA under accession code EGAS50000000170. Due to the sensitive nature of the data derived from human subjects, including personal health information, analyses and sharing of data from this project must comply with the General Data Protection Regulation (GDPR). How to get access to the data is described here: https://www.mn.uio.no/bils/english/groups/rounge-group/crcbiome/. R-scripts used in this study are available at: https://github.com/Rounge-lab/sex-differences

Author contributions

TBR and PB were responsible for the conception and design of the study. ASK, CBJ, and EB analysed the data. VB performed the sample preparation and lab work. ASK, CBJ, EB, EA, EB, PB, and TBR interpreted the data. ASK and CBJ drafted the manuscript. All authors have revised, commented on, and approved the final submitted manuscript.

References

1.   Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

2.   Global Cancer Observatory. Cancer Tomorrow | IARC - https://gco.iarc.who.int/tomorrow [Internet].   [Available   from: https://gco.iarc.fr/tomorrow/en/dataviz/trends?types=0_1&sexes=1_2&mode=population&group _populations=0&multiple_populations=1&multiple_cancers=1&cancers=8_41&populations=900 &apc=cat_ca20v1.5_ca23v-1.5&group_cancers=1.

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

4. Baraibar I, Ros J, Saoudi N, Salva F, Garcia A, Castells MR, et al. Sex and gender
perspectives in colorectal cancer. ESMO Open. 2023;8(2):101204.

5. Atkin W, Wooldrage K, Parkin DM, Kralj-Hans I, MacRae E, Shah U, et al. Long term
effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible
Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389(10076):1299-311.

6. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al.
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med.
2012;366(25):2345-57.

7. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only
sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized
Controlled Trial--SCORE. J Natl Cancer Inst. 2011;103(17):1310-22.

8. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Effect of flexible
sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial.
JAMA. 2014;312(6):606-15.

9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing
mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer
Control Study. N Engl J Med. 1993;328(19):1365-71.

10. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of
screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-71.

11. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal
occult blood screening for colorectal cancer. Br J Surg. 2008;95(8):1029-36.

12. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al.
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet.
1996;348(9040):1472-7.

13. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal
cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637-49.

14. Council of the European Union. Council Recommendation on strengthening prevention
through early detection: A new EU approach on cancer screening replacing Council
Recommendation 2003/878/EC. Off J Eur Union. 2022;100:1-10.

15. Randel KR, Botteri E, de Lange T, Schult AL, Eskeland SL, El-Safadi B, et al. Performance
of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity
Thresholds. Aliment Pharmacol Ther. 2025;61(1):122-31.

16. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer
Screening. Gastroenterology. 2020;158(2):418-32.

17.   Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical
faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer.
2011;104(11):1779-85.

18.   Hultcrantz R. Aspects of colorectal cancer screening, methods, age and gender. J Intern
Med. 2021;289(4):493-507.

19.   Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing.
Am J Gastroenterol. 2010;105(11):2457-64.

20.   Brenner H, Qian J, Werner S. Variation of diagnostic performance of fecal
immunochemical testing for hemoglobin by sex and age: results from a large screening cohort.
Clin Epidemiol. 2018;10:381-9.

21.   White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A. A review of
sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis,
cancer stage and survival in the UK. BMC cancer. 2018;18(1):906.

22.   Njor SH, Rasmussen M, Friis-Hansen L, Andersen B. Varying fecal immunochemical test
screening cutoffs by age and gender: a way to increase detection rates and reduce the number
of colonoscopies. Gastrointest Endosc. 2022;95(3):540-9.

23.   Grobbee EJ, Wieten E, Hansen BE, Stoop EM, de Wijkerslooth TR, Lansdorp-Vogelaar I,
et al. Fecal immunochemical test-based colorectal cancer screening: The gender dilemma. United
European Gastroenterol J. 2017;5(3):448-54.

24.   Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities
in colorectal cancer risk. World J Gastroenterol. 2015;21(17):5167-75.

25.   Streett SE. Endoscopic colorectal cancer screening in women: can we do better?
Gastrointest Endosc. 2007;65(7):1047-9.

26.   Witte TN, Enns R. The difficult colonoscopy. Can J Gastroenterol. 2007;21(8):487-90.

27.   Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Long-Term
Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in
Women and Men: A Randomized Trial. Ann Intern Med. 2018;168(11):775-82.

28.   Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-
12.

29.   DeWeerdt S. Microbiome: Microbial mystery. Nature. 2015;521(7551):S10-1.

30.   Garrett WS. The gut microbiota and colon cancer. Science. 2019;364(6446):1133-5.

31.   Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev
Clin Oncol. 2023;20(7):429-52.

32.   Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical
applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690-704.

33.   Janney A, Powrie F, Mann EH. Host-microbiota maladaptation in colorectal cancer.
Nature. 2020;585(7826):509-17.

34.   Xing C, Du Y, Duan T, Nim K, Chu J, Wang HY, et al. Interaction between microbiota and
immunity and its implication in colorectal cancer. Front Immunol. 2022;13:963819.

35.   Chen Y, Chen YX. Microbiota-Associated Metabolites and Related Immunoregulation in
Colorectal Cancer. Cancers (Basel). 2021;13(16):4054.

36.   Zheng DP, Liwinski T, Elinav E. Interaction between microbiota and immunity in health
and disease. Cell Res. 2020;30(6):492-506.

37.   Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation, and colorectal
cancer. Intest Res. 2018;16(3):338-45.

38.   Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The Genus Alistipes: Gut
Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. Front Immunol.
2020;11:906.

39.   Sanchez-Alcoholado L, Ordonez R, Otero A, Plaza-Andrade I, Laborda-Illanes A, Medina
JA, et al. Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity
and Colorectal Cancer. Int J Mol Sci. 2020;21(18).

40.   Wu Z, Huang Y, Zhang R, Zheng C, You F, Wang M, et al. Sex differences in colorectal
cancer: with a focus on sex hormone-gut microbiome axis. Cell Commun Signal. 2024;22(1):167.

41.   Rodriguez-Santiago Y, Garay-Canales CA, Nava-Castro KE, Morales-Montor J. Sexual
dimorphism in colorectal cancer: molecular mechanisms and treatment strategies. Biol Sex Differ.
2024;15(1):48.

42.   Zhou YL, Hong J. Gut microbiota: Guardians of the female gut health. Cancer Cell.
2023;41(8):1392-4.

43.   Cheng WT, Kantilal HK, Davamani F. The Mechanism of Bacteroides fragilis Toxin
Contributes to Colon Cancer Formation. Malays J Med Sci. 2020;27(4):9-21.

44.   Spigaglia P, Barbanti F, Germinario EAP, Criscuolo EM, Bruno G, Sanchez-Mete L, et al.
Comparison of microbiological profile of enterotoxigenic Bacteroides fragilis (ETBF) isolates from
subjects with colorectal cancer (CRC) or intestinal pre-cancerous lesions versus healthy
individuals and evaluation of environmental factors involved in intestinal dysbiosis. Anaerobe.
2023;82:102757.

45.   Arima K, Zhong R, Ugai T, Zhao M, Haruki K, Akimoto N, et al. Western-Style Diet, pks
Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective
Cohort Studies. Gastroenterology. 2022;163(4):862-74.

46.   Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM,
Nomburg J, et al. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli.
Nature. 2020;580(7802):269-73.

47.   Sengupta S, Muir JG, Gibson PR. Does butyrate protect from colorectal cancer? J
Gastroenterol Hepatol. 2006;21(1 Pt 2):209-18.

48.   Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of fecal
metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med.
2019;25(4):679-89.

49.   Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, et al. Clostridium butyricum, a butyrate-
producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and
gut microbiota. Cancer Lett. 2020;469:456-67.

50.   Zwezerijnen-Jiwa FH, Sivov H, Paizs P, Zafeiropoulou K, Kinross J. A systematic review
of microbiome-derived biomarkers for early colorectal cancer detection. Neoplasia.
2023;36:100868.

51.   Fusco W, Bricca L, Kaitsas F, Tartaglia MF, Venturini I, Rugge M, et al. Gut microbiota in
colorectal cancer: From pathogenesis to clinic. Best Pract Res Clin Gastroenterol.
2024;72:101941.

52.   Valeri F, Endres K. How biological sex of the host shapes its gut microbiota. Front
Neuroendocrinol. 2021;61:100912.

53.   Vemuri R, Sylvia KE, Klein SL, Forster SC, Plebanski M, Eri R, et al. The microgenderome
revealed: sex differences in bidirectional interactions between the microbiota, hormones,
immunity and disease susceptibility. Semin Immunopathol. 2019;41(2):265-75.

54.   Yoon K, Kim N. Roles of Sex Hormones and Gender in the Gut Microbiota. J
Neurogastroenterol Motil. 2021;27(3):314-25.

55.   Thackray VG. Sex, Microbes, and Polycystic Ovary Syndrome. Trends Endocrinol Metab.
2019;30(1):54-65.

56.   Yang X, Li P, Qu Z, Zhuang J, Wu Y, Wu W, et al. Gut bacteria and sex differences in
colorectal cancer. J Med Microbiol. 2023;72(6).

57.   Wang L, Tu YX, Chen L, Zhang Y, Pan XL, Yang SQ, et al. Male-Biased Gut Microbiome
and Metabolites Aggravate Colorectal Cancer Development. Adv Sci (Weinh).
2023;10(25):e2206238.

58.   Liao H, Li C, Ai Y, Kou Y. Gut microbiome is more stable in males than in females during
the development of colorectal cancer. J Appl Microbiol. 2021;131(1):435-48.

59.   Li Q, Chan H, Liu WX, Liu CA, Zhou Y, Huang D, et al. Carnobacterium maltaromaticum
boosts intestinal vitamin D production to suppress colorectal cancer in female mice. Cancer Cell.
2023;41(8):1450-65 e8.

60.   Song CH, Kim N, Nam RH, Choi SI, Yu JE, Nho H, et al. Changes in Microbial Community
Composition Related to Sex and Colon Cancer by Nrf2 Knockout. Front Cell Infect Microbiol.
2021;11:636808.

61. Song CH, Kim N, Nam RH, Choi SI, Jang JY, Kim EH, et al. The Possible Preventative
Role of Lactate- and Butyrate-Producing Bacteria in Colorectal Carcinogenesis. Gut Liver.
2024;18(4):654-66.

62. Yu S, Chu J, Wu Y, Zhuang J, Qu Z, Song Y, et al. Third-generation PacBio sequencing
to explore gut bacteria and gender in colorectal cancer. Microb Pathog. 2024;192:106684.

63. Lattanzi G, Perillo F, Diaz-Basabe A, Caridi B, Amoroso C, Baeri A, et al. Estrogen-related
differences in antitumor immunity and gut microbiome contribute to sexual dimorphism of
colorectal cancer. Oncoimmunology. 2024;13(1):2425125.

64. Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon
Cancer. Front Oncol. 2020;10:607909.

65. Chang YM, Kang YR, Lee YG, Sung MK. Sex differences in colonic gene expression and
fecal microbiota composition in a mouse model of obesity-associated colorectal cancer. Scientific
reports. 2024;14(1):3576.

66. World Cancer Research Fund/American Institute for Cancer Research. Continuous
update project report. Food, nutrition, physical activity, and the prevention of colorectal cancer.
American Institute for Cancer Research Washington (DC); 2011.

67. Wild CP, Weiderpass E, Stewart BW. World cancer report. 2020.

68. Song M, Chan AT. Environmental Factors, Gut Microbiota, and Colorectal Cancer
Prevention. Clin Gastroenterol Hepatol. 2019;17(2):275-89.

69. Song M, Chan AT, Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk
of Colorectal Cancer. Gastroenterology. 2020;158(2):322-40.

70. Kvaerner AS, Birkeland E, Bucher-Johannessen C, Vinberg E, Nordby JI, Kangas H, et
al. The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the
gut microbiome in colorectal cancer screening participants. BMC cancer. 2020.

71. Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, et al. Colorectal Cancer
Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results
From a Randomized Trial. Gastroenterology. 2021;160(4):1085-96 e5.

72. Andersen LF, Solvoll K, Johansson LR, Salminen I, Aro A, Drevon CA. Evaluation of a
food frequency questionnaire with weighed records, fatty acids, and alpha-tocopherol in adipose
tissue and serum. Am J Epidemiol. 1999;150(1):75-87.

73. Andersen LF, Tomten H, Haggarty P, Lovo A, Hustvedt BE. Validation of energy intake
estimated from a food frequency questionnaire: a doubly labelled water study. Eur J Clin Nutr.
2003;57(2):279-84.

74. Andersen LF, Veierod MB, Johansson L, Sakhi A, Solvoll K, Drevon CA. Evaluation of
three dietary assessment methods and serum biomarkers as measures of fruit and vegetable
intake, using the method of triads. Br J Nutr. 2005;93(4):519-27.

75.   Carlsen MH, Lillegaard IT, Karlsen A, Blomhoff R, Drevon CA, Andersen LF. Evaluation
of energy and dietary intake estimates from a food frequency questionnaire using independent
energy expenditure measurement and weighed food records. Nutr J. 2010;9(1):37.

76.   Brunvoll SH, Thune I, Frydenberg H, Flote VG, Bertheussen GF, Schlichting E, et al.
Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a
biomarker in breast cancer patients during treatment. Nutr J. 2018;17(1):94.

77.   Nes M, Frost Andersen L, Solvoll K, Sandstad B, Hustvedt BE, Lovo A, et al. Accuracy of
a quantitative food frequency questionnaire applied in elderly Norwegian women. Eur J Clin Nutr.
1992;46(11):809-21.

78.   Norwegian Food Safety Authority. Norwegian Food Composition Database 2019
[Internet]. 2019 [cited 2025 20.02]. Available from: www.matvaretabellen.no.

79.   Shams-White MM, Brockton NT, Mitrou P, Romaguera D, Brown S, Bender A, et al.
Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer Research
(WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System. Nutrients.
2019;11(7).

80.   Shams-White MM, Romaguera D, Mitrou P, Reedy J, Bender A, Brockton NT. Further
Guidance in Implementing the Standardized 2018 World Cancer Research Fund/American
Institute for Cancer Research (WCRF/AICR) Score. Cancer Epidemiology Biomarkers &
Prevention. 2020;29(5):889-94.

81.   Kvaerner AS, Andersen AR, Henriksen HB, Knudsen MD, Johansen AMW, Hjartaker A,
et al. Associations of the 2018 World Cancer Research Fund/American Institute of Cancer
Research (WCRF/AICR) cancer prevention recommendations with stages of colorectal
carcinogenesis. Cancer Med. 2023;12(13):14806-19.

82.   Istvan P, Birkeland E, Avershina E, Kvaerner AS, Bemanian V, de Vos W, et al. Exploring
the gut virome in fecal immunochemical test stool samples reveals novel associations with
lifestyle in a large population-based study. medRxiv. 2023:2023.08. 24.23294548.

83.   Rounge TB, Meisal R, Nordby JI, Ambur OH, de Lange T, Hoff G. Evaluating gut
microbiota profiles from archived fecal samples. BMC Gastroenterol. 2018;18(1):171.

84.   Blanco-Miguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, et al. Extending
and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn
4. Nat Biotechnol. 2023;41(11):1633-44.

85.   Beghini F, McIver LJ, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating
taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery
3. Elife. 2021;10.

86.   Wang Y, Wang Q, Huang H, Huang W, Chen Y, McGarvey PB, et al. A crowdsourcing
open platform for literature curation in UniProt. PLoS Biol. 2021;19(12):e3001464.

87.   Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology:
tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-9.

88.   Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, et al. Gene Ontology
Consortium. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224(1).

89.   Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained
equations in R. Journal of statistical software. 2011;45:1-67.

90.   Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin P, O'Hara R, et al. Vegan:
community ecology package. Ordination methods, diversity analysis and other functions for
community and vegetation ecologists. 2015:2.3-1.

91.   Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, et al. Multivariable
association discovery in population-scale meta-omics studies. PLoS Comput Biol.
2021;17(11):e1009442.

92.   Kvaerner AS, Birkeland E, Avershina E, Botteri E, Bucher-Johannessen C, Dines Knudsen
M, et al. The association between alcohol consumption and colorectal carcinogenesis is partially
mediated by the gut microbiome. medRxiv. 2024:2024.10. 17.24315656.

93.   Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal
Mediation Analysis. Journal of Statistical Software. 2014;59(5).

94.   Steen J, Loeys T, Moerkerke B, Vansteelandt S. medflex: An R Package for Flexible
Mediation Analysis using Natural Effect Models. Journal of Statistical Software. 2017;76(11):1-
46.

95.   Wickham H, Averick M, Bryan J, Chang W, McGowan LDA, François R, et al. Welcome
to the Tidyverse. Journal of open source software. 2019;4(43):1686.

96.   Kassambara A. rstatix: Pipe-friendly framework for basic statistical tests. R package
version 06 0. 2020.

97.   Venables WN, Ripley BD. Modern applied statistics with S-PLUS: Springer Science &
Business Media; 2013.

98.   Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, et al. Metagenomic
analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and
a link with choline degradation. Nat Med. 2019;25(4):667-78.

99.   Young C, Wood HM, Fuentes Balaguer A, Bottomley D, Gallop N, Wilkinson L, et al.
Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples
Shows the Potential to Improve Screening Accuracy. Clin Cancer Res. 2021;27(8):2246-54.

100. Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, et al. Metagenomic
and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in
colorectal cancer. Nat Med. 2019;25(6):968-76.

101. Selby K, Levine EH, Doan C, Gies A, Brenner H, Quesenberry C, et al. Effect of Sex, Age,
and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and
Meta-analysis. Gastroenterology. 2019;157(6):1494-505.

102.   World Cancer Research Fund/American Institute for Cancer Research. Diet, nutrition,
physical activity and colorectal cancer. Continous Update Project Expert Report 2018; 2018.

103.   Godos J, Bella F, Torrisi A, Sciacca S, Galvano F, Grosso G. Dietary patterns and risk of
colorectal adenoma: a systematic review and meta-analysis of observational studies. J Hum Nutr
Diet. 2016;29(6):757-67.

104.   Erben V, Carr PR, Holleczek B, Stegmaier C, Hoffmeister M, Brenner H. Dietary patterns
and risk of advanced colorectal neoplasms: A large population based screening study in
Germany. Prev Med. 2018;111:101-9.

105.   Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and
adenomatous polyps: a meta-analysis. Gastroenterology. 2008;134(2):388-95.

106.   Ben Q, Wang L, Liu J, Qian A, Wang Q, Yuan Y. Alcohol drinking and the risk of colorectal
adenoma: a dose-response meta-analysis. Eur J Cancer Prev. 2015;24(4):286-95.

107.   Bailie L, Loughrey MB, Coleman HG. Lifestyle Risk Factors for Serrated Colorectal Polyps:
A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(1):92-104.

108.   He X, Hang D, Wu K, Nayor J, Drew DA, Giovannucci EL, et al. Long-term Risk of
Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps.
Gastroenterology. 2020;158(4):852-61 e4.

109.   Kvaerner AS, Birkeland E, Vinberg E, Hoff G, Hjartaker A, Rounge TB, et al. Associations
of red and processed meat intake with screen-detected colorectal lesions. Br J Nutr.
2023;129(12):2122-32.

110.   Knudsen MD, Botteri E, Holme O, Hjartaker A, Song M, Thiis-Evensen E, et al. Association
between lifestyle and site-specific advanced colorectal lesions in screening with faecal
immunochemical test and sigmoidoscopy. Dig Liver Dis. 2021;53(3):353-9.

111.   Knudsen MD, de Lange T, Botteri E, Nguyen DH, Evensen H, Steen CB, et al. Favorable
lifestyle before diagnosis associated with lower risk of screen-detected advanced colorectal
neoplasia. WJG. 2016;22(27):6276-86.

112.   Joo HJ, Lee HS, Jang BI, Kim DB, Kim JH, Park JJ, et al. Sex-specific differences in
colorectal cancer: A multicenter retrospective cohort study. Cancer Rep (Hoboken).
2023;6(8):e1845.

113.   Niedermaier T, Heisser T, Gies A, Guo F, Amitay EL, Hoffmeister M, et al. To what extent
is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results
from a large German screening population. Intl Journal of Cancer. 2021;149(11):1877-86.

114.   Calcaterra V, Rossi V, Massini G, Regalbuto C, Hruby C, Panelli S, et al. Precocious
puberty and microbiota: The role of the sex hormone-gut microbiome axis. Front Endocrinol
(Lausanne). 2022;13:1000919.

115.   Zhang X, Zhong H, Li Y, Shi Z, Ren H, Zhang Z, et al. Sex- and age-related trajectories of
the adult human gut microbiota shared across populations of different ethnicities. Nat Aging.
2021;1(1):87-100.

116. Sinha T, Vich Vila A, Garmaeva S, Jankipersadsing SA, Imhann F, Collij V, et al. Analysis
of 1135 gut metagenomes identifies sex-specific resistome profiles. Gut Microbes.
2019;10(3):358-66.

117. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level
analysis of gut microbiome variation. Science. 2016;352(6285):560-4.

118. de la Cuesta-Zuluaga J, Kelley ST, Chen Y, Escobar JS, Mueller NT, Ley RE, et al. Age-
and Sex-Dependent Patterns of Gut Microbial Diversity in Human Adults. mSystems. 2019;4(4).

119. Bucher-Johannessen C, Senthakumaran T, Avershina E, Birkeland E, Hoff G, Bemanian
V, et al. Species-level verification of Phascolarctobacterium association with colorectal cancer.
mSystems. 2024;9(10):e0073424.

120. Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P, et al.
Long-term follow-up of colorectal cancer screening attendees identifies differences in
Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing. Front Oncol.
2023;13:1183039.

121. Senthakumaran T, Moen AEF, Tannaes TM, Endres A, Brackmann SA, Rounge TB, et al.
Microbial dynamics with CRC progression: a study of the mucosal microbiota at multiple sites in
cancers, adenomatous polyps, and healthy controls. Eur J Clin Microbiol Infect Dis.
2023;42(3):305-22.

122. Hua H, Sun Y, He X, Chen Y, Teng L, Lu C. Intestinal Microbiota in Colorectal Adenoma-
Carcinoma Sequence. Front Med (Lausanne). 2022;9:888340.

123. Doden HL, Pollet RM, Mythen SM, Wawrzak Z, Devendran S, Cann I, et al. Structural and
biochemical characterization of 20beta-hydroxysteroid dehydrogenase from Bifidobacterium
adolescentis strain L2-32. The Journal of biological chemistry. 2019;294(32):12040-53.

124. McCurry MD, D'Agostino GD, Walsh JT, Bisanz JE, Zalosnik I, Dong X, et al. Gut bacteria
convert glucocorticoids into progestins in the presence of hydrogen gas. Cell. 2024;187(12):2952-
68 e13.

125. Jiang L, Fei H, Tong J, Zhou J, Zhu J, Jin X, et al. Hormone Replacement Therapy
Reverses Gut Microbiome and Serum Metabolome Alterations in Premature Ovarian
Insufficiency. Front Endocrinol (Lausanne). 2021;12:794496.

126. Song CH, Kim N, Nam RH, Choi SI, Lee HN, Surh YJ. 17beta-Estradiol supplementation
changes gut microbiota diversity in intact and colorectal cancer-induced ICR male mice. Scientific
reports. 2020;10(1):12283.

127. Gupta A, Dhakan DB, Maji A, Saxena R, P KV, Mahajan S, et al. Association of
Flavonifractor plautii, a Flavonoid-Degrading Bacterium, with the Gut Microbiome of Colorectal
Cancer Patients in India. mSystems. 2019;4(6).

128. Qin Y, Tong X, Mei WJ, Cheng Y, Zou Y, Han K, et al. Consistent signatures in the human
gut microbiome of old- and young-onset colorectal cancer. Nat Commun. 2024;15(1):3396.

129.   Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, et al. Dysbiosis of human gut microbiome in
young-onset colorectal cancer. Nat Commun. 2021;12(1):6757.

130.   Lee JWJ, Plichta DR, Asher S, Delsignore M, Jeong T, McGoldrick J, et al. Association of
distinct microbial signatures with premalignant colorectal adenomas. Cell Host Microbe.
2023;31(5):827-38 e3.

131.   Sprotte S, Brinks E, Neve H, Franz C. Complete genome sequence of the novel virulent
phage PMBT24 infecting Enterocloster bolteae from the human gut. Heliyon. 2024;10(8):e28813.

132.   Giri R, Hoedt EC, Khushi S, Salim AA, Bergot AS, Schreiber V, et al. Secreted NF-kappaB
suppressive microbial metabolites modulate gut inflammation. Cell Rep. 2022;39(2):110646.

133.   Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and
Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature.
Gastroenterol Res Pract. 2014;2014:872725.

134.   Bai Z, Zhang N, Jin Y, Chen L, Mao Y, Sun L, et al. Comprehensive analysis of 84
Faecalibacterium prausnitzii strains uncovers their genetic diversity, functional characteristics,
and potential risks. Front Cell Infect Microbiol. 2022;12:919701.

135.   Berthelsen M, Berstad P, Randel KR, Hoff G, Natvig E, Holme O, et al. The impact of
driving time on participation in colorectal cancer screening with sigmoidoscopy and faecal
immunochemical blood test. Cancer Epidemiol. 2022;80:102244.

136.   Botteri E, Hoff G, Randel KR, Holme O, de Lange T, Bernklev T, et al. Characteristics of
nonparticipants in a randomised colorectal cancer screening trial comparing sigmoidoscopy and
faecal immunochemical testing. Int J Cancer. 2022;151(3):361-71.
911